Vonoprazan: Difference between revisions
CSV import Tag: Manual revert |
CSV import |
||
| Line 1: | Line 1: | ||
'''Vonoprazan''' is a [[potassium-competitive acid | {{DISPLAYTITLE:Vonoprazan}} | ||
== Overview == | |||
[[File:Vonoprazan_structure.svg|thumb|right|Chemical structure of Vonoprazan]] | |||
'''Vonoprazan''' is a medication that belongs to a class of drugs known as [[potassium-competitive acid blockers]] (P-CABs). It is primarily used for the treatment of [[gastroesophageal reflux disease]] (GERD) and [[peptic ulcer disease]]. Unlike traditional [[proton pump inhibitors]] (PPIs), vonoprazan works by competitively blocking the potassium-binding site of the [[H+/K+ ATPase]] enzyme in the stomach lining, leading to a reduction in gastric acid secretion. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Vonoprazan acts by inhibiting the [[H+/K+ ATPase]] enzyme, which is responsible for the final step in the production of gastric acid in the stomach. By blocking the potassium-binding site of this enzyme, vonoprazan effectively reduces the secretion of gastric acid, providing relief from acid-related disorders. | |||
Vonoprazan | == Clinical Uses == | ||
Vonoprazan is used in the management of several acid-related gastrointestinal conditions, including: | |||
* [[Gastroesophageal reflux disease]] (GERD) | |||
* [[Peptic ulcer disease]] | |||
* [[Helicobacter pylori]] eradication therapy, often in combination with antibiotics | |||
== | == Advantages over Proton Pump Inhibitors == | ||
[[File:Vonoprazan_structure.svg|thumb|left|Vonoprazan offers rapid onset of action compared to PPIs]] | |||
One of the main advantages of vonoprazan over traditional PPIs is its rapid onset of action. Vonoprazan begins to reduce gastric acid secretion more quickly than PPIs, which require activation in the acidic environment of the stomach. This rapid action can lead to faster symptom relief for patients. | |||
Additionally, vonoprazan is less affected by genetic variations in [[CYP2C19]], an enzyme that metabolizes many PPIs, leading to more consistent therapeutic effects across different patient populations. | |||
== Side Effects == | == Side Effects == | ||
Common side effects of vonoprazan may include: | |||
* [[Diarrhea]] | |||
* [[Constipation]] | |||
* [[Nausea]] | |||
* [[Headache]] | |||
Serious side effects are rare but can include [[hypomagnesemia]] and [[Clostridium difficile]] infection. | |||
== | == Pharmacokinetics == | ||
Vonoprazan is well absorbed after oral administration and has a long half-life, allowing for once-daily dosing. It is metabolized in the liver and excreted primarily in the urine. | |||
Vonoprazan | |||
== Related pages == | |||
* [[Proton pump inhibitor]] | * [[Proton pump inhibitor]] | ||
* [[Gastroesophageal reflux disease]] | * [[Gastroesophageal reflux disease]] | ||
| Line 28: | Line 40: | ||
* [[Helicobacter pylori]] | * [[Helicobacter pylori]] | ||
[[Category:Pharmacology]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 11:33, 15 February 2025
Overview[edit]
Vonoprazan is a medication that belongs to a class of drugs known as potassium-competitive acid blockers (P-CABs). It is primarily used for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer disease. Unlike traditional proton pump inhibitors (PPIs), vonoprazan works by competitively blocking the potassium-binding site of the H+/K+ ATPase enzyme in the stomach lining, leading to a reduction in gastric acid secretion.
Mechanism of Action[edit]
Vonoprazan acts by inhibiting the H+/K+ ATPase enzyme, which is responsible for the final step in the production of gastric acid in the stomach. By blocking the potassium-binding site of this enzyme, vonoprazan effectively reduces the secretion of gastric acid, providing relief from acid-related disorders.
Clinical Uses[edit]
Vonoprazan is used in the management of several acid-related gastrointestinal conditions, including:
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Helicobacter pylori eradication therapy, often in combination with antibiotics
Advantages over Proton Pump Inhibitors[edit]
One of the main advantages of vonoprazan over traditional PPIs is its rapid onset of action. Vonoprazan begins to reduce gastric acid secretion more quickly than PPIs, which require activation in the acidic environment of the stomach. This rapid action can lead to faster symptom relief for patients.
Additionally, vonoprazan is less affected by genetic variations in CYP2C19, an enzyme that metabolizes many PPIs, leading to more consistent therapeutic effects across different patient populations.
Side Effects[edit]
Common side effects of vonoprazan may include:
Serious side effects are rare but can include hypomagnesemia and Clostridium difficile infection.
Pharmacokinetics[edit]
Vonoprazan is well absorbed after oral administration and has a long half-life, allowing for once-daily dosing. It is metabolized in the liver and excreted primarily in the urine.
